Evidence map›Paper›PMID 40933598›Full record

ReviewResearch in pharmaceutical sciences2025

Octreotide and direct/indirect lung injury.

Ghasem Zarei, Zahra Pezeshki, Samira Choopani, Mehdi Nematbakhsh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Protective Role of Octreotide in Acute and Chronic Lung Injuries.International journal of preventive medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ghasem ZareiDepartment of Physiology, Medical School, Isfahan University of Medical Sciences, I.R. Iran.
Zahra PezeshkiDepartment of Physiology, Medical School, Isfahan University of Medical Sciences, I.R. Iran.
Samira ChoopaniDepartment of Physiology, Medical School, Isfahan University of Medical Sciences, I.R. Iran.
Mehdi NematbakhshDepartment of Physiology, Medical School, Isfahan University of Medical Sciences, I.R. Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Lung injury is one of the most important diseases, which is accompanied by hypoxemia, organ failure, and a high mortality rate. There are several symptoms and causes of lung injuries. In the past years, special attention has been given to investigating the pathophysiology and the treatment of this disease. Octreotide, as an anti-inflammatory, anti-secretory, tissue-repairing, and anti-fibrotic drug, has been considered and administered for the treatment of lung injury. This review article considered the pharmacological effects of octreotide on physiopathological conditions in patients or animal models that have direct or indirect lung injury. Search strategy and findings: Keywords including "octreotide" OR "sandostatin" AND "lung injury" OR "ARDS" OR "respiratory distress" OR "lung fibrosis" were searched in the database of PubMed, and 44 articles were found. According to the direct or indirect lung injury, the articles were classified. Conclusion: It appears that octreotide is a protective drug for the treatment of direct and indirect lung injuries, exhibiting anti-inflammatory, anti-hypersecretory, anti-fibrotic, and anti-neutrophil permeability effects, while also increasing endogenous antioxidants. However, there is still room for extensive research to fully clarify the effectiveness of octreotide for direct or indirect lung injury.

Indexed as

Acute respiratory distress syndromeLung fibrosisLung injuryOctreotide

Identifiers

PMID40933598
PMCPMC12419580

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.